Key Highlights

  • Curis (NASDAQ:CRIS) was trading down 11.54% at USD 0.5058 in pre-market on Friday, November 13, 2026, implying a prior close of about USD 0.57 (calculated), after a third-quarter report scheduled for November 12.
  • Shares were near USD 0.85 on November 5, 2026, so the pre-market price is about 40% lower (calculated), and a published preview showed a range of USD 0.33 to USD 2.08 since the last report.
  • The company raised USD 8.5 million in a private Placement announced on October 16, 2026, after a USD 5.6 million public offering on August 13, according to published headlines.
  • Analysts expected a loss of USD 2.29 a share for the quarter, and year-ago Revenue was USD 3.2 million, according to a published preview of the report.

Third-Quarter Report Lands Before the Pre-Market Drop

Curis (NASDAQ:CRIS) scheduled its third-quarter 2026 financial and operating results for after the close on November 12, 2026, with a conference call the same evening. The released figures could not be retrieved, so this article does not state revenue, net loss or cash for the quarter. No other company announcement for November 11 to November 13 was found. The timing makes the report a plausible trigger for the 11.54% drop, but that is an inference, not a confirmed cause. Pre-market Volume is thin, so the move is the figure of record for pre-market only. The preview also said the company had given no formal guidance and that analysts had published no revenue consensus, which leaves the loss per share as the main comparison point once the release is read.

Emavusertib, the Lead Program, and a Funding Question

Curis is a biotechnology company whose lead asset is emavusertib, an oral IRAK4 and FLT3 inhibitor in Phase 2 studies for relapsed hematologic cancers. It is being tested with ibrutinib in relapsed or refractory primary CNS lymphoma and with zanubrutinib in chronic lymphocytic leukemia. The drug has FDA Orphan Drug Designation for primary CNS lymphoma, acute myeloid leukemia and myelodysplastic syndromes, and the company licenses it from Aurigene through a 2015 collaboration. The AML studies are substantially complete, and further AML development depends on additional funding. That makes the cash position the core issue for Curis (NASDAQ:CRIS).

Financings, a Reverse Split Vote and the Sub-USD 1 Price

Published headlines list a USD 8.5 million private placement on October 16, a USD 5.6 million public offering on August 13 and a vote on a reverse stock split. A preview stated that the loss was USD 4.02 a share last quarter against USD 0.49 a year earlier, and that the 200-day average was USD 8.72, figures that suggest share-count adjustments and were not reconciled. At USD 0.5058, the shares trade below the USD 1 minimum bid level for Nasdaq, although no specific notice was found. Further offerings could dilute holders, and a low-priced biotech can swing on few trades. The next markers are the release details, the cash balance, the split vote outcome and Phase 2 emavusertib updates, including any data in primary CNS lymphoma or chronic lymphocytic leukemia.

Where Things Stand

The results are the most likely trigger, since Curis (NASDAQ:CRIS) reported after the close on November 12, but the figures were not retrieved and no cause is confirmed. The shares are about 40% below their November 5 level and under USD 1, after two financings and with a reverse split vote on record. Emavusertib continues in Phase 2, while AML development hinges on funding. Watch the cash runway statement, the split outcome and any listing notice.